BURLINGAME, Calif. -- (BUSINESS WIRE) -- Igenica, Inc., a company focused on the discovery and development of innovative antibodies and antibody-drug conjugates (ADCs) for the treatment of cancer, today announced the appointment of oncology expert and former Genentech executive Gwen A. Fyfe, M.D., as an independent member of the company’s Board of Directors.
“Gwen’s proven expertise overseeing the successful development of major oncology drugs is invaluable to Igenica as we advance our pipeline, and most imminently as we prepare to enter the clinic with our lead program, IGN523, in early 2014,” said Mary Haak-Frendscho, Ph.D., chief executive officer of Igenica. “Gwen’s appointment comes at a pivotal time in Igenica’s evolution as we begin development of our first product candidate and expand our proprietary platform to accelerate the development and delivery of effective homogeneous ADC therapies that have enormous potential to address critical needs of cancer patients.”
Dr. Fyfe brings more than 20 years of drug development experience, including key roles in the development and approvals of Rituxan®, Herceptin®, Avastin® and Tarceva®. At Genentech, Inc. (now a member of the Roche Group), she served as vice president, oncology development and vice president, Avastin Franchise Team. She was a member of both the Development Oversight Committee and the Research Review Committee, responsible for approving product advancement from research into clinical development. Dr. Fyfe is a globally recognized oncology expert and frequently invited member of National Cancer Institute working groups and grant committees, American Society of Clinical Oncologists oversight committees, and Institute of Medicine panels. She currently serves on the Boards of Directors of Array BioPharma, Inc. and Infinity Pharmaceuticals, Inc. Dr. Fyfe is a graduate of Washington University School of Medicine and a board-certified pediatric oncologist.
“I am very pleased to join Igenica’s Board of Directors and have been impressed with both Igenica’s platform technology and the high quality and experience of its executive team,” said Dr. Fyfe. “The combination of an integrated suite of pipeline-enabling capabilities and a proven team of therapeutic antibody leaders positions Igenica well to drive rapid development of high impact medicines. I look forward to collaborating with the Igenica team to realize the mission of delivering effective biotherapeutics, including ADCs, to patients with cancer.”
About Igenica, Inc.
Igenica, Inc. is focused on the discovery and development of antibodies and antibody-drug conjugates (ADCs) for the treatment of cancer. Igenica is the only biotherapeutic company that fully powers the ADC development spectrum from a patient-based approach to target and functional antibody discovery to the generation and manufacturing of homogeneous ADCs. Igenica’s integrated discovery engine has generated a robust pipeline of site-specific ADC candidates and functional antibodies to address critical needs of cancer patients. Led by a proven team of leaders with expertise in the development of therapeutic antibodies and ADCs, Igenica is funded by a premier group of life science investors including The Column Group, OrbiMed Advisors, 5AM Ventures and Third Rock Ventures. For more information, please visit www.igenica.com.